Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

E.B. Garon; B.C. Cho; A. Luft; J. Alatorre-Alexander; S.L. Geater; D. Trukhin; S-W. Kim; G. Ursol; M. Hussein; F.L. Lim; C-T. Yang; L.H. Araujo; H. Saito; N. Reinmuth; N. Medic; H. Mann; X. Shi; S. Peters; T.S.K. Mok; M. Johnson

doi:10.1016/j.annonc.2022.02.014

YUHSpace

BROWSE

0 127

Cited 0 times in

Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

Authors: E.B. Garon ; B.C. Cho ; A. Luft ; J. Alatorre-Alexander ; S.L. Geater ; D. Trukhin ; S-W. Kim ; G. Ursol ; M. Hussein ; F.L. Lim ; C-T. Yang ; L.H. Araujo ; H. Saito ; N. Reinmuth ; N. Medic ; H. Mann ; X. Shi ; S. Peters ; T.S.K. Mok ; M. Johnson